

31st May, 2023

To,
The Manager - Corporate Relationship
Dept.
BSE Limited
P. J. Towers, Dalal Street
Fort, Mumbai - 400 001

To,
The Manager - Corporate Compliance
National Stock Exchange of India Limited
Exchange Plaza, Plot No.C-1,
G Block, BKC, Bandra (E),
Mumbai 400 051

BSE Scrip Code: - 524500

NSE SYMBOL: - KILITCH

Sub: Press Release

Dear Sir,

Please find enclosed herewith our Press Release relating to financial results for the fourth quarter ended 31st March, 2023, which we shall be releasing after sending this letter to you.

Request you to take note of the same and acknowledge the receipt.

Thanking you,

Yours' Faithfully,

For **Kilitch Drugs (India) Limited**

Mukund Mehta
Managing Director
DIN: 00147876





Kilitch Drugs (India) Ltd.

KILITCH DRUGS (INDIA) LIMITED REPORTS 69.87% INCREASE IN Q4 FY23 PROFIT

Mumbai May 29, 2023, Kilitch Drugs India Limited is a Leading MSME multinational manufacturer of Injectable in India and Ethiopia, has announced its audited Financial Results for the Q4 & FY23.

Financials at a Glance:

Q4 FY23:

Particulars (₹ crore)	Q4 FY23	Q4 FY22	YoY Change
Operation Revenue	43.28	32.03	↑ 35.12%
EBITDA	8.12	4.74	↑ 71.31%
EBITDA (%)	18.76%	14.80%	↑ 396 BPS
Net Profit	5.13	3.02	↑ 69.87%
Net Profit Margin (%)	11.85%	9.43%	↑ 242 BPS
EPS (₹)	3.29	1.94	↑ 69.59%

FY23:

Particulars (₹ crore)	FY23	FY22	YoY Change
Operating Revenue	117.78	105.15	↑ 12.00%
EBITDA	21.77	15.56	↑ 39.91%
EBITDA (%)	18.48%	14.80%	↑ 368 BPS
Net Profit	15.72	10.53	↑ 49.29
Net Profit Margin (%)	13.35%	10.01%	↑ 334 BPS
EPS (₹)	10.09	6.76	↑ 49.26%

Commenting on this **Mr. Mukund Mehta, Managing Director of Kilitch Drugs (India) Limited** said

“We experienced a remarkable 69.87 % increase in net profit, which can be attributed to the splendid demand for our products during this period.

I am particularly pleased with the results of our efforts to improve pricing and exercise rigorous cost control, which led to an impressive ~400 basis point jump in our EBITDA margin. This accomplishment reflects the dedication and hard work of our team.

Looking ahead, we are confident that our positive momentum will continue in coming years. Our commitment to growth is evident through our ongoing capacity expansion initiatives, aimed at meeting the rising demand from both domestic and international markets.

With our solid position in the industry, we are well-prepared to seize the opportunities that lie ahead and continue our upward trajectory. I am excited about the future prospects of Kilitch Drugs and remain committed to driving our success in the coming years.”

About Kilitch Drugs (India) Limited:

Established in 1992, Kilitch Drug (India) is a successful pharmaceutical solution company. Company has major focus in African region and have strong foothold across key African countries with 350 products in 26 African countries.

The Company has manufacturing plant located in Mumbai with a dedicated dry powder section and small volume liquid ampoules and vial. In 2018 the Company has started greenfield project in Ethiopia for Cephalosporins Injectables. The Company's manufacturing plants are certified by WHO, WHO GMP, ISO 9001, ISO 13845 etc.

The Company's strong clientele includes Intas, Mankind, Indoco Remedies to name among few.

Disclaimer:

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

Contacts:

Ms. Pushpa Nyoupane

Tel: 022 61214100

Tel direct: 022 61214122

Mobile: 9145753142

Email: pushpanyoupane@kilitch.com